Alzamend Neuro, Inc. - Common Stock
Educational technical indicators — not investment advice. TradeOrgs does not place trades.
$100,000.00 invested would be worth $55,199.39 (-44.8%) · Full backtester →
Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Live data was unavailable (the free feed can be rate-limited or blocked by region/host), so sample figures are shown. Set FINNHUB_API_KEY for a reliable fallback.
Sentiment is a keyword-based read of the headline — a rough signal, not advice.
Fundamental data is informational only — not investment advice.